No Data
No Data
Aier Ophthalmology (300015): 1Q profit growth was steady, optimistic about the upward trend throughout the year
Under the influence of internal and external factors, the profit side continued to grow steadily in 1Q24, maintaining that “buy” rated companies achieved revenue/net profit of 203.7/3.36 billion yuan in 23 years (yoy +26.4%/+33.1%), 1Q2
Express News | Citi downgraded Aier Ophthalmology's rating to neutral.
Aier Ophthalmology (300015): 1Q24 profit slightly exceeded expectations, global service network continues to expand
The 2023 full-year results are in line with market expectations, and the 1Q24 profit side slightly exceeds market expectations, and Aier Ophthalmology announced 2023 and 1Q24 results: 2023 revenue of 20.37 billion yuan, an increase of 26.4% over the previous year, returning to the mother
Nomura Adjusts Aier Eye Hospital's Price Target to 15.35 Yuan From 22.14 Yuan, Keeps at Buy
04:55 AM EDT, 04/26/2024 (MT Newswires) -- Nomura Adjusts Aier Eye Hospital's Price Target to 15.35 Yuan From 22.14 Yuan, Keeps at Buy Price (RMB): ¥12.63, Change: ¥+0.39, Percent Change: +3.19%
Guojin Securities released a research report on April 26 stating that it gave Aier Ophthalmology (300015.SZ) a purchase rating. The main reasons for the rating include: 1) revenue shows strong resilience, and the number of outpatients and surgeries has in
Guojin Securities released a research report on April 26 stating that it gave Aier Ophthalmology (300015.SZ) a purchase rating. The main reasons for the rating include: 1) revenue shows strong resilience, and the number of outpatients and surgeries has increased steadily; 2) profitability has steadily increased due to the scale effect; 3) the country is steadily advancing the “1+8+N” strategy and strengthening strategic cooperation overseas. (Mainichi Keizai Shimbun)
Aier Ophthalmology (300015) Company Review: Performance highlights the resilience of leading companies and steady progress in domestic and international layouts
Performance Brief Review On April 25, 2024, the company released its 2023 annual report. In 2023, the company achieved revenue of 20.367 billion yuan (+26% year-on-year) and realized net profit of 3.359 billion yuan (+
No Data